Survival in patients with primary soft-tissue sarcomas treated within 6 years

Peiper, Matthias; Zurakowski, David; Schwarz, Rudolf; Weh, H. J.; Zornig, C.

doi:10.1007/s004320050155

Cited by 11 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Local recurrence has previously been found to be related to patient survival [35], but our analysis did not find a significant influence of local recurrence on patient prognosis, underlining other recently published data about sSTS and STS in general [35, 36]. In a recent report from our institution we reported that local recurrences of soft tissue sarcoma can be resected in almost all cases, with no significant adverse effect on survival [19].…”

Section: Discussionsupporting

confidence: 68%

“…In the present series, T2 tumors were negatively associated with freedom from local recurrence. Our results accentuate the need for a radical surgical approach to the primary tumor; for all subcutaneous tumors a radical resection achieving three-dimensional tumor-free resection margins may be associated with improved freedom of local recurrence [19]. The prognostic influence of initial optimal resection on local resection in spite of initial re-excision was demonstrated in a recent study that supports the demand for treatment of STS in specialized centers [20].…”

Section: Discussionsupporting

confidence: 62%

“…The observation by Rydholm and Gustafson Our multivariate analysis revealed that the size of the primary tumor is the single risk factor of local recurrence. The observation by other investigators [19,[21][22][23][24] that quality of resection is a prognostic factor for local recurrence could not be verified. This is most likely so because in our series only one of the 6 patients who underwent R1 resection went on to develop a local recurrence.…”

Section: Discussionmentioning

confidence: 79%

See 2 more Smart Citations

Superficial Soft Tissue Sarcomas of the Extremities and Trunk

et al. 2009

View full text Add to dashboard Cite

Patients with sSTS who are > or = 60 years of age or who have G3 tumors have a high risk of distant metastases. Patients with T2 tumors have an elevated risk for local recurrence. Certainly all patients with sSTS should be in a tight after-care program to allow early diagnosis of local recurrence or distant metastases. Age < 60 years, tumor grade G1/2, no positive regional lymph nodes (N0), and a R0 resection are significant prognostic factors for survival.

show abstract

Section: Discussionsupporting

confidence: 68%

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 79%

See 1 more Smart Citation

Superficial Soft Tissue Sarcomas of the Extremities and Trunk

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The most important prognostic factor identified so far is the quality of surgical treatment at initial diagnosis [2]. Meanwhile, new prognostic factors are sought in order to specifically assess the importance of an adjuvant or palliative therapy.…”

Section: Introductionmentioning

confidence: 99%

Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study

et al. 2014

View full text Add to dashboard Cite

BackgroundNew prognostic markers may be of value in determining survival and informing decisions of adjuvant treatment in the heterogeneous group of soft tissue sarcomas known as malignant fibrous sarcomas (MFS). Increased CD44 expression has been associated with a better outcome in cancers such as bladder tumors and could potentially relate to cell-cell interaction as a marker for potential invasion/metastasis. The aim of this pilot study was to determine if there is a correlation between the expression rate of CD44 in adult patients with MFS and clinical outcomes.MethodsThe clinical outcome of 34 adult MFS patients (19 males and 15 females, average age 62 years, median 63 years, range: 38–88 years) who underwent surgical treatment were evaluated. Twenty-five of these patients had additional adjuvant radiotherapy. Extracted RNA from sarcoma tissues was used to measure the transcripts of CD44s (standard form) and isoform expression.The pooled data for each variant of CD44 was divided in half at the median expression value into two equally sized groups (low and high). Survival modeling and multivariate analysis were used with these two groups to determine if there were differences in survival times and whether this was independent of known factors such as tumor stage/grade, patient age and resection margin status.ResultsHigh CD44s and low of CD44v6 expression significantly correlated with an improved outcome (P <0.05 and P <0.02, respectively) whereas CD44v8 and hCD44 (isoforms) did not. Differences in survival were apparent within 6–12 months of operation with >30% difference in survival between low/high expressions at 5 years. These finding were independent of the other measured MFS survival predictors, though the group was homogenous.ConclusionsHigh CD44s and low CD44v6 expression may be an independent predictor of improved survival in MFS patients in this pilot data. This is contrary to other MFS data, which did not account for the CD44 isoforms but is confirmed by data from other cancer types. Further investigation is needed to confirm CD44 isoform expression data as a relevant survival biomarker and whether it could be used to inform clinical decisions such as adjuvant therapy.

show abstract

“…Die adjuvante postoperative Strahlentherapie hat allerdings keinen Einfluss auf das Gesamtüberleben [23,24]. Dieses bestätigen auch Peiper et al bei subfaszialen Weichteilsarkomen größer als 5 cm (T2b) [29]. Heute wird die Kombination von radikaler R0-Resektion und postoperativer Strahlentherapie als Standardvorgehen bei subfaszialen sowie T2 Weichteilsarkomen angesehen [30].…”

Section: Adjuvante Strahlentherapie (Postoperativ Bei Negativen Oder unclassified

Radiotherapie der Weichteilsarkome – Teil einer multidisziplinären Strategie

Pape

Orth

Engers

et al. 2008

Wien Klin Wochenschr

View full text Add to dashboard Cite

The management of soft tissue sarcoma has evolved from a solitary surgical treatment to an interdisciplinary multimodal approach including radiotherapy. These fundamental changes are the result of increased knowledge in tumor biology, radiation sensitivity and the improvement in modern radiation therapy techniques. A successful effective therapy regimen strongly depends on distinct preoperative diagnostics, preoperative conception of the surgical intervention and an experienced oncological team. Of significant importance for the prognosis is early diagnosis as well as tumor excision with a wide negative margin. However, even after complete wide resection in sano, the use of postoperative radiotherapy can further improve local control and should therefore be applied to the majority of patients. Consequently, radiotherapy should only be omitted in cases in which the tumor has been excised with a very wide negative margin; this implies, however, high quality of surgery and distinct histopathological analysis. Patients with non- or questionable resectable tumors, should be referred for pre-operative radiotherapy in order to improve the surgical results. Recent studies have underlined the efficiency of modern radiotherapy regimens. The different radiotherapy regimens will be highlighted against the background of tumor stage and tumor resectibility.

show abstract

Survival in patients with primary soft-tissue sarcomas treated within 6 years

Cited by 11 publications

References 34 publications

Superficial Soft Tissue Sarcomas of the Extremities and Trunk

Superficial Soft Tissue Sarcomas of the Extremities and Trunk

Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study

Radiotherapie der Weichteilsarkome – Teil einer multidisziplinären Strategie

Contact Info

Product

Resources

About